INTRODUCTION
Use and abuse of drugs, alcohol, and tobacco contribute significantly to the health burden of society. The 2009 National Survey on Drug Use and Health reported that recent (within the past month) use of illicit drugs, binge or heavy alcohol ingestion, and use of tobacco products occurred in 8.7%, 23.7%, and 27.7%, respectively, of the population 12 years or older. 1 Numerous case reports have documented the use of a variety of drugs by women of childbearing age (Table 1) . In trauterine exposure to certain drugs may cause congenital anomalies and/or fetal growth restriction, increase the risk of preterm birth, produce signs of withdrawal or toxicity in the neonate, or impair normal neurodevelopment. 2 Fetal exposure to marijuana, the illicit drug most commonly used by pregnant women, does not cause clinically important neonatal withdrawal signs but may have subtle effects on long-term neurobehavioral outcomes. 3 With the use of computer-assisted interviewing techniques that preserved confiden tiality, the 2009 National Survey on Drug Use and Health noted that 4.5% of pregnant women 15 to 44 years of age reported recent use of illicit drugs (eg, marijuana, cocaine, hallucinogens, heroin, meth amphetamines, and nonmedical use of prescription drugs). Binge or heavy drinking in the first trimester was reported by 11.9%, and recent tobacco use was reported by 15.3%. Rates of recent illicit drug use and smoking were lower among pregnant compared with non pregnant women across all age groups, except for those 15 to 17 years of age. In the latter age group, the rates of illicit drug use and smoking were higher among those who were pregnant compared with those who were not pregnant (15.8% vs 13.0% and 20.6% vs 13.9%, respectively). The reported rates of illicit drug use most likely underestimate true rates, because the percentage of pregnant women who report the recent use of illicit drugs on screening interviews can DET, diethyltryptamine; DMT, dimethyltryptamine; LSD, lysergic acid diethylamide; MDA, methylenedioxyamphetamine; MDEA, 3,4-methylenedioxyethamphetamine; MDMA, 3,4-methylene dioxymethamphetamine (ecstasy); and MMDA, 3-methoxy-4,5-methylenedioxyamphetamine. a Adapted from Milhorn. 160 be substantially lower than that de termined by drug screening using bi ological samples. For infants, the use of International Classification of Dis eases, Ninth Revision (ICD-9)-based hos pital discharge databases to determine the incidence of neonatal drug with drawal secondary to intrauterine expo sure has in the past underestimated the incidence of this condition. 4 Data compiled by the Agency for Healthcare Research and Quality and by the Florida Department of Health attest to an increased incidence and/or recog nition of neonatal withdrawal syn drome (ICD-9 code 779.5). Nationally, the number of infants coded at discharge with neonatal withdrawal increased from 7653 in 1995 to 11 937 in 2008. In Florida, the number of newborns dis charged with ICD-9 code 779.5 climbed by more than 10-fold, from 0.4 to 4.4 discharges per 1000 live births, from 1995 to 2009. An indeterminate part of these observed increases has resulted from more liberal use of prescription opiates in pregnant women to palliate a wide variety of etiologies of acute or chronic pain. In a recent report, chronic use of narcotic prescriptions (use for ≥1 intrapartum month) among pregnant women cared for at a single clinic increased fivefold from 1998 to 2008, and 5.6% of infants delivered to these women manifested signs of neonatal withdrawal. 5 Signs characteristic of neonatal with drawal have been attributed to intra uterine exposure to a variety of drugs (Table 2) . Other drugs cause signs in neonates because of acute toxicity. Chronic in utero exposure to a drug (eg, alcohol) can lead to permanent phe notypical and/or neurodevelopmental behavioral abnormalities consistent with drug effect. Signs and symptoms of withdrawal worsen as drug levels decrease, whereas signs and symp toms of acute toxicity abate with drug elimination. Clinically important neo natal withdrawal most commonly re sults from intrauterine opioid exposure. The constellation of clinical findings associated with opioid withdrawal has been termed the neonatal abstinence syndrome (NAS). Among neonates ex posed to opioids in utero, withdrawal signs will develop in 55% to 94%. [6] [7] [8] [9] Neonatal withdrawal signs have also been described in infants exposed an tenatally to benzodiazepines, 10, 11 bar biturates, 12, 13 and alcohol.
14,15
COCAINE AND OTHER STIMULANTS
An abstinence syndrome after intra uterine exposure to central nervous system (CNS) stimulants such as co caine and amphetamine has not been clearly defined. Many studies that have assessed behavior and neurologic signs in cocaine-exposed infants have used scoring systems that were designed to evaluate opioid withdrawal. Neuro behavioral abnormalities 16, 17 frequently occur in neonates with intrauterine cocaine exposure, most frequently on the second or third postnatal days. 18 These abnormalities may include ir ritability, hyperactivity, tremors, highpitched cry, and excessive sucking. Because cocaine or its metabolites may be detected in neonatal urine for as long as 7 days after delivery, 18 observed abnormalities in exposed in fants may reflect drug effect rather than withdrawal. In an unmasked study, 6%, 14%, and 35% of infants exposed to cocaine only, heroin only, or cocaine plus heroin, respectively, qualified for treatment on the basis of scoring. 19 Several studies that used masked eval uators found that cocaine-exposed in fants had either no 20, 21 or minimal 22 withdrawal signs compared with cocainenaïve infants (ie, those never exposed). Eyler et al 16 conducted a prospective controlled study of 3 groups of infants: 1 group had no documented exposure to cocaine by history or by maternal and infant urine testing; a second group was cocaine exposed but had negative urine screening at birth; and a third group had cocaine metabolites de tected in neonatal urine. Observers masked to infant status performed as sessments using the Brazelton Neo natal Behavioral Assessment Scale. 23 Infants who were positive for cocaine metabolites did not differ significantly from metabolite-negative infants with a history of exposure nor from cocainenaïve infants. These findings supported neither a withdrawal nor a drug tox icity syndrome. Cocaine-exposed infants have been described as having a higher incidence of abnormal auditory brain stem responses and EEGs, compared with nonexposed infants. 24, 25 In another study, infants with heavy exposure to cocaine had similar Brazelton findings at 2 to 3 days of age as did infants with light or no exposure; however, by 17 days of age, heavily exposed infants were more excitable and demonstrated poorer state regulation. 26 No published studies have carefully evaluated phar macologic treatment of infants with signs attributable to prenatal cocaine exposure.
Methamphetamine abuse has been reported among pregnant women, 27 although overall rates are low com pared with cocaine and appear to have decreased in the general popu lation between 2006 and 2008. 1 Meth amphetamine is an extremely potent sympathomimetic agent that induces euphoria and increases alertness and self-confidence, because it produces a massive efflux of dopamine in the CNS. Pregnant women who abuse metham phetamine are at increased risk of preterm birth, placental abruption, fetal distress, and intrauterine growth re striction at rates similar to those for pregnant women who use cocaine. In 1 study, only 4% of infants exposed to methamphetamine were treated for drug withdrawal, but it was not pos sible to exclude concomitant abuse of other drugs as contributory in all cases. 27 There are reports of long-term adverse neurotoxic effects of in utero methamphetamine exposure on behav ior, cognitive skills, and physical dex terity. 28 adverse drug reaction reports, 32 and prospective studies 33, 34 linked thirdtrimester use of SSRIs in pregnant women to a constellation of neonatal signs that include continuous crying, ir ritability, jitteriness, and/or restlessness; shivering; fever; tremors; hypertonia or rigidity; tachypnea or respiratory dis tress; feeding difficulty; sleep distur bance; hypoglycemia; and seizures. 35 The onset of these signs ranged from several hours to several days after birth and usually resolved within 1 to 2 weeks. In 1 infant exposed to parox etine, signs persisted through 4 weeks of age. 36 In severely affected infants, a short-term course of chlorpromazine provided measurable relief of symp 36 toms.
Several authors have discussed whether these signs are better explained by se rotonin syndrome (attributable to in creased serotonin concentration in the intersynaptic cleft) or by SSRI with drawal (attributable to a relative hypo serotonergic state). 30, 32, 35, [37] [38] [39] [40] In adults, treatment with a single SSRI may cause mild to moderate serotonin syn drome, but severe signs are more likely to occur when 2 or more drugs that increase serotonin concentration by different mechanisms are pre scribed. 35 In adults, serotonin syn drome is characterized by the following triad of clinical signs: changes in men tal status (agitation, confusion); auto nomic hyperactivity (fever, tachycardia, tachypnea, diaphoresis, mydriasis); and neuromuscular abnormalities (tremor, clonus, hyperreflexia, hypertonia). On the other hand, serotonin withdrawal in adults manifests with subjective symp toms that include anxiety, headache, PEDIATRICS Volume 129, Number 2, February 2012 nausea, fatigue, low mood, and, rarely, extrapyramidal signs such as dysto nia. Hence, in most cases, the clinical syndrome reported among neonates born to mothers on SSRI treatment is consistent with a gradual resolution of a hyperserotonergic condition rather than with the evolution of a hyposer otonergic state. Still, in a few cases, drug withdrawal may be a better ex planation. 35 Biochemical studies that correlate serial serum SSRI (or active metabo lite) concentrations and markers of CNS serotonin activity (eg, 5-hydrox yindoleacetic acid , a metabo lite of serotonin) with changes in clinical signs could be helpful in dif ferentiating toxicity from withdrawal. In adults, cerebrospinal fluid concen trations of 5-HIAA (but not serum concentrations of serotonin) correlate inversely with increased CNS serotonin activity that results from SSRI treat ment. One prospective study compared concentrations of SSRI and active metabolites at birth, 2 days of life, and 2 weeks of life; cord blood monoamine and metabolite; and serial serotoner gic scores in infants born to mothers on treatment with SSRIs and those of SSRI-naïve control infants. 39 The in fants born to mothers on SSRIs had an average serotonergic score four fold greater than SSRI-naïve infants. Cord blood 5-HIAA concentrations were inversely related to the initial serotonergic score, and the resolution of neonatal signs correlated with rapid declines in serially measured serum SSRI and metabolite concen trations. 39 These results do support drug toxicity rather than drug with drawal as the cause of clinical signs. Recent authors have suggested the terms "serotonin discontinuation syn drome" 34 or "prenatal antidepressant exposure syndrome." 41 Although 1 study reported decreased pain reactivity at 2 months of age in infants with prenatal exposure to SSRIs, 42 several recent reviews have not identified adverse neurodevelop mental outcomes among infants born to women treated with SSRIs dur ing pregnancy. 30, 34, 43, 44 SSRI treatment should be continued during preg nancy at the lowest effective dose, because withdrawal of medication may have harmful effects on the mother-infant dyad. Clinicians should be aware that infants are at risk for manifesting clinical signs of drug toxicity or withdrawal over the first week of life and arrange for early follow-up after the initial hospital dis charge. Ideally, recommendations about lactation and breastfeeding should be made in consideration of what is known about the differences among drugs in a therapeutic class vis-à-vis the ratio of human milk to maternal plasma drug concentration, the likely total daily infant drug dose (as a fraction of the daily maternal drug dose normalized for weight), and the ratio of infant to maternal plasma drug concentration. However, in the absence of known adverse effects (eg, diminished suck, sleep disturbances, decreased growth), what constitutes an acceptable fractional drug dose or ratio of plasma concentrations is arbitrary-is 0.10 acceptable but 0.20 not? Paroxetine is the only SSRI for which the ratio of infant to maternal plasma concentrations is low and uniformly <0.10. 45 Fortinguerra et al 46 documented that paroxetine, sertra line, and fluvoxamine are minimally excreted in human milk and provide the infant <10% of the maternal daily dose (normalized for weight). Yet, Weissman et al 45 cite studies in which 6% and 33% of the reported paired infant to maternal plasma concentra tion ratios for sertraline and fluvox amine, respectively, are >0.10. A mother on treatment with an SSRI who desires to nurse her infant should be counseled about the e543 benefits of breastfeeding as well as the potential risk that her infant may continue to be exposed to a measureable level of the SSRI with unknown long-term effects.
OPIOIDS
Opioids are a class of natural, en dogenous, and synthetic compounds that activate primarily µ-opioid (but also κ-and δ-opioid) receptors in the CNS to produce supraspinal analgesia. Other acute effects include sedation, euphoria, miosis, respiratory depres sion, and decreased gastrointestinal motility. Prolonged use results in phys ical and psychological dependence. As a class, opioids demonstrate a nar row therapeutic index. On the other hand, the interpatient range of dose necessary to achieve a similar thera peutic effect is fairly wide because of genetic differences in pharmacoki netics and pharmacodynamics. 47 Mor phine is 1 of many natural opioids that can be extracted from the opium poppy. Codeine, heroin (diacetylmor phine), hydromorphone (Dilaudid), fen tanyl (Sublimaze), and methadone are examples of synthetic opioids. Endog enous opioids include enkephalins, endorphins, and endomorphins. The term opiate refers to a subclass of alkaloid opioids. Methadone exerts secondary effects by acting as an N-methyl-D-aspartate receptor antago nist, blocking the actions of glutamate, the primary excitatory neurotrans mitter in the CNS. Opioids acutely in hibit the release of noradrenaline at synaptic terminals. With chronic opi oid exposure, tolerance develops as the rate of noradrenaline release over time increases toward normal. Abrupt discontinuation of exogenous opioids results in supranormal re lease of noradrenaline and produces the autonomic and behavioral signs and symptoms characteristic of with drawal.
Opioid abuse in pregnant women presents additional risks for the fetus and newborn. Opioids are small lipo philic molecular weight compounds that cross placental and blood-brain barriers. Active or passive maternal detoxification is associated with in creased risk of fetal distress and fe tal loss. Maintenance programs with methadone (a full µ-opioid agonist and a Food and Drug Administration [FDA] schedule II controlled substance) for pregnant women can sustain opi oid concentrations in the mother and fetus in ranges that minimize opioid craving, suppress abstinence symp tomatology, block heroin-induced eu phoria, and prevent fetal stress. Other benefits from this once controversial treatment are optimization of prenatal care and general maternal physical and mental health, as well as antici pation of potential withdrawal signs in the newborn infant. Disadvantages of methadone include the extremely un likely achievement of successful de toxification after delivery and a more severe and prolonged course of NAS compared with heroin exposure. These issues have encouraged the develop ment of other synthetic opioids as al ternative treatments to methadone.
Subsequent to the Drug Addiction Treatment Act of 2000 that allowed office-based treatment of addiction by using FDA schedule III to V drugs, the synthetic opioid buprenorphine (a partial µ-opioid agonist) was ap proved by the FDA in 2002 as a sched ule III controlled substance for the treatment of opioid dependence. Nei ther methadone nor buprenorphine is approved for use in pregnant women, and both are categorized by the FDA as class C pregnancy drugs. None theless, buprenorphine, either alone (Subutex) or in combination with nal oxone (Suboxone), has been used both as a first-line treatment of heroin ad diction and as a replacement drug for methadone. Recent results from the Maternal Opioid Treatment: Human Experimental Research study suggest that buprenorphine has some advan tages to methadone as a treatment of opioid addiction in pregnant women. Infants born to mothers treated with buprenorphine had shorter hospital stays (10 vs 17.5 days), had shorter treatment durations for NAS (4.1 vs 9.9 days), and required a lower cumu lative dose of morphine (1.1 vs 10.4 mg) compared with infants born to moth ers on methadone maintenance. 48 
CLINICAL PRESENTATION OF OPIOID WITHDRAWAL
The clinical presentation of NAS varies with the opioid, the maternal drug history (including timing of the most recent use of drug before delivery), maternal metabolism, net transfer of drug across the placenta, placental metabolism (W. Snodgrass, MD, PhD, personal communication, 2008), infant metabolism and excretion, and other factors. In addition, maternal use of other drugs and substances such as cocaine, barbiturates, hypnoticssedatives, and cigarettes may influ ence the severity and duration of NAS. Because opioid receptors are concentrated in the CNS and the gastrointestinal tract, the predom inant signs and symptoms of pure opioid withdrawal reflect CNS irrita bility, autonomic overreactivity, and gas trointestinal tract dysfunction (Table 3) . Excess environmental stimuli and hun ger will exacerbate the perceived se verity of NAS.
Onset of signs attributable to neonatal withdrawal from heroin often begins within 24 hours of birth, whereas withdrawal from methadone usually commences around 24 to 72 hours of age. 49 For both opioids, evidence of withdrawal may be delayed until 5 to 7 days of age or later, which is typi cally after hospital discharge. 50 For found that infants who required rescue treatment had lower cord blood meth adone concentrations and that, in all but 1 infant, methadone concentrations were undetectable in the serum at 48 hours. Doberczak 65 noted that faster declines in postnatal blood methadone concentrations were associated with more severe CNS withdrawal.
Preterm Infants
Preterm infants have been described as being at lower risk of drug with drawal with less severe and/or pro longed courses. Infants born at <35 weeks' gestation whose mothers re ceived methadone maintenance had significantly lower total and CNS ab stinence scores than did term infants of mothers receiving similar metha done dosages. 64 In a more recent study, lower gestational age corre lated with a lower risk of neonatal withdrawal. 68 The apparent decreased severity of signs in preterm infants may relate to developmental immatu rity of the CNS, differences in total drug exposure, or lower fat depots of drug. Alternatively, the clinical evaluation of the severity of absti nence may be more difficult in preterm infants, because scoring tools to describe withdrawal were largely developed in term or late preterm infants. 76, 77 In a retrospective study, Dysart et al 78 compared the length of hospital stay, duration of medication, and cumulative medication exposure for preterm and term infants born to mothers enrolled in a methadone maintenance program. Infants were evaluated by using an abstinence scoring system 77 infants exposed to buprenorphine, 1 study found that onset of withdrawal peaked at 40 hours and that signs were most severe at 70 hours of age. 51 The different time courses re flect variations in the half-lives of drug elimination. However, if 1 week or longer has elapsed between the last maternal opioid use and delivery of the infant, the incidence of neona tal withdrawal is relatively low. 52 The incidence and severity of NAS are greater in infants exposed to metha done compared with those exposed to buprenorphine 48 or heroin. Still, se vere withdrawal has been described in 0 to 50% of buprenorphine-exposed infants. [53] [54] [55] In the acute phase, seiz ures have occurred in 2% to 11% of infants withdrawing from opioids 49, 50, 56 ; however, abnormal EEG results with out overt seizure activity have been 57, 58 reported in >30% of neonates. Subacute signs of opioid withdrawal may last up to 6 months. 59 Seizures also may be associated with withdrawal from a variety of non narcotic drugs (eg, barbiturates, 12, 14 alcohol, 14 and sedative-hypnotics 60, 61 ). The mechanism and significance of seizures associated with withdrawal are unclear. Withdrawal from ethanol begins early, in general, during the first 3 to 12 hours after delivery. 12, 15 Diagnosis of sedative withdrawal is more difficult, because classically it appears after the first few days of [69] [70] [71] [72] [73] [74] This lack of consensus is explained in part by dif ferent approaches to the management of antenatal methadone maintenance therapy. There were substantial var iations in the mean and range of daily methadone dose in the populations studied. Studies that found no corre lation tended to enroll infants born to mothers who had been prescribed higher doses of methadone (50-200 mg/day), whereas those that did note a relationship between maternal dose and NAS sequelae reported lower maternal doses (eg, <50 mg/day) or included women undergoing partial detoxification. 67 Another potential ex planatory factor is the significant in terindividual variability in maternal methadone metabolism. 75 As a re sult, cumulative fetal exposure can with a neonatal opiate solution. All adverse outcomes were reduced in the preterm cohort.
Abuse of Multiple Drugs
The abuse of multiple drugs during pregnancy is not uncommon, 79 but its effect on the occurrence and severity of neonatal abstinence is controver sial. In 1 study, abstinence scores of infants whose mothers abused co caine and methadone were similar to the scores of infants whose mothers received high-dose maintenance meth adone. 64 In another study, the neuro behavioral scores of infants exposed to intrauterine cocaine were similar to those of infants exposed to both cocaine and methadone. 80 Conversely, an unmasked study reported higher abstinence scores in infants exposed to both cocaine and heroin in compar ison with those exposed to heroin or cocaine alone. 19 Infants born to moth ers maintained on methadone who were also heavy smokers (>20 ciga rettes per day) demonstrated higher withdrawal scores that peaked later than infants born to light smokers. 81 A 1989 case report linked the adminis tration of naloxone for the treatment of apnea in a baby born to a mother with recent methadone ingestion to the onset of seizures. The seizures resolved after morphine treatment but did not respond to administration of phenobarbital or diazepam. 82 For this reason, maternal use of opiates during pregnancy has remained a relative contraindication to the use of naloxone for the treatment of apnea or hypoventilation during the transition period after birth.
DIFFERENTIAL DIAGNOSIS
The presence of maternal character istics known to be associated with drug abuse during pregnancy can be considered an indication to screen for intrauterine drug exposure. These characteristics include absent, late, or inadequate prenatal care; a previously documented or admitted history of drug abuse; a previous unexplained late fetal demise; precipitous labor; abruptio placentae; hypertensive episodes; se vere mood swings; cerebrovascular accidents; myocardial infarction; and repeated spontaneous abortions. 80, [83] [84] [85] [86] [87] [88] The legal implications of testing and the need for consent from the mother may vary among the states. 89 Each hospital should consider adopting a policy for maternal and newborn screening to avoid discriminatory practices and to comply with local laws.
Withdrawal signs in the newborn may mimic other conditions, such as in fection, hypoglycemia, hypocalcemia, hyperthyroidism, intracranial hemor rhage, hypoxic-ischemic encephalopa thy, and hyperviscosity. 90 If none of these diagnoses is readily apparent, a detailed maternal drug history should be obtained that includes interviewing the mother about drug use and abuse by her partner, friends, and parents, in addition to queries about the mother' s prescription and nonprescription drug use. 90, 91 Because maternal self-reporting underestimates drug exposure and maternal urine screening during pregnancy fails to identify many cases of drug use, 83 appropriate neonatal drug screening should be performed. Conversely, no clinical signs should be attributed solely to drug withdrawal on the basis of a positive maternal history without a careful assessment to exclude other causes.
Screening is most commonly accom plished by using neonatal urine speci mens. A urine sample must be collected as soon as possible after birth, be cause many drugs are rapidly me tabolized and eliminated. 90, 92, 93 Even so, a positive urine screening result may only reflect recent drug use. Al cohol is detectable in neonatal urine for 6 to 16 hours after the last ma ternal ingestion. Amphetamines, ben zodiazepines, cocaine metabolites, and opioids are usually cleared within 1 to 3 days after birth. Marijuana and co caine metabolites may be detectable for weeks, depending on maternal usage. 94 Drugs that are excreted in the hep atobiliary system as well as drugs excreted by the fetal kidneys into the amniotic fluid are concentrated in meconium. Hence, meconium analysis is most useful when the history and clinical presentation strongly suggest neonatal withdrawal, but the maternal and neonatal urine screening results are negative. Drawbacks of testing for drugs in meconium are that it is not typically performed by hospitals and that results are often not available for days to weeks. Meconium must be collected before it is contaminated by transitional, human milk, or formula stools-otherwise, the assay may not be valid or the reference laboratory may reject the sample. Assay of me conium, although not conclusive if the results are negative, is more likely to identify infants of drug-abusing mothers than is the testing of infant or maternal urine. 95, 96 Other speci mens that have been tested in re search laboratories are maternal and neonatal hair. 97, 98 Recently, testing of umbilical cord tissue by using drug class-specific immunoassays was shown to be in concordance with testing of paired meconium specimens at rates of 97%, 95%, 99%, and 91% for the detection of amphetamines, opiates, co caine, and cannabinoids, respectively. 99 The availability of this tissue from the moment of birth (in contrast to the inherent delay in collecting urine or meconium) may foster the adoption of this method of testing. " prob ably because it is a relatively simple metric with good sensitivity for iden tifying clinically important withdrawal. The modified Neonatal Abstinence Scoring System (Fig 1) , 101 is the pre dominant tool used in the United States. 102 This more comprehensive instrument assigns a cumulative score based on the interval observation of 21 items relating to signs of neonatal withdrawal. 103 In 1 study, administra tion of this scoring system with in fants verified not to have been exposed to prenatal opiates by meconium anal ysis resulted in a stable median score of 2 during each of the first 3 days of life, with 95th percentile scores of 5.5 and 7 on days 1 and 2, respectively.
ASSESSMENT AND NONPHARMACOLOGIC TREATMENT

104
Infants at risk for NAS should be carefully monitored in the hospital for the development of signs consis tent with withdrawal. The infant needs to be carefully observed to recognize fever, dehydration, or weight loss promptly. The goals of therapy are to ensure that the infant achieves ade quate sleep and nutrition to establish a consistent pattern of weight gain and begins to integrate into a social environment. Maternal screening for comorbidities, such as HIV or hepatitis C virus infections and polydrug abuse, needs to be performed. Additional supportive care in the form of intra venous fluids, replacement electro lytes, and gavage feedings may be necessary to stabilize the infant' s con dition in the acute phase and obviate the need for pharmacologic interven tion. When possible, and if not other wise contraindicated, mothers who adhere to a supervised drug treat ment program should be encouraged to breastfeed so long as the infant con tinues to gain weight. Breastfeeding or the feeding of human milk has been associated with less severe NAS that presents later and less frequently re quires pharmacologic intervention. 107, 108 Methadone is present in very low con centrations in human milk. Cumula tive daily intake of methadone in fully breastfed infants has been estimated to range from 0.01 to 0.15 mg/day in the first 30 days of life 109 and 0.15 to 0.30 mg/day between 30 and 180 days of age. 110 Similarly, the amount of buprenorphine excreted in human milk is small. Although more informa tion is needed to evaluate long-term neurodevelopmental outcome of in fants exposed to small quantities of buprenorphine, there is no clear rea son to discourage breastfeeding in mothers who adhere to methadone or buprenorphine maintenance treat 111 ment.
Each nursery should adopt a protocol for the evaluation and management of neonatal withdrawal, and staff should be trained in the correct use of an abstinence assessment tool. In a re cent survey of accredited US neo natology fellowship programs, only 55% had implemented a written NAS protocol, and only 69% used a pub lished abstinence scoring system. 102 
RATIONALE AND COMPARATIVE EVIDENCE FOR PHARMACOLOGIC TREATMENT
Drug therapy is indicated to relieve moderate to severe signs of NAS and to prevent complications such as fever, weight loss, and seizures if an infant does not respond to a committed program of nonpharmacologic sup port. Since the introduction of the abstinence scales in 1975, published reports have documented that the decision to initiate pharmacologic treatment has been based on single or serial withdrawal scores. However, no studies to date have compared the use of different withdrawal score thresh olds for initiating pharmacologic in tervention on short-term outcomes (eg, severity and duration of with drawal signs, weight gain, duration of hospitalization, need for pharmaco logic treatment, or cumulative drug exposure). Withdrawal from opioids or sedative-hypnotic drugs may be life-threatening, but ultimately, drug withdrawal is a self-limited process. Unnecessary pharmacologic treatment will prolong drug exposure and the duration of hospitalization to the pos sible detriment of maternal-infant bond ing. The only clearly defined benefit of pharmacologic treatment is the shortterm amelioration of clinical signs.
Studies have not addressed whether long-term morbidity related to neona tal drug withdrawal is decreased by pharmacologic management of affected infants, or whether continued postnatal drug exposure augments the risk of neurobehavioral and other morbidities. It is possible that pharmacologic ther apy of the infant may introduce or re inforce a maternal disposition to rely on drugs for the treatment of infant discomfort or annoying behavior. 112 Clinicians have treated NAS with a va riety of drug preparations, including opioids (tincture of opium, neonatal morphine solution, methadone, and paregoric), barbiturates (phenobar bital), benzodiazepines (diazepam, lorazepam), clonidine, and phenothia zines (chlorpromazine). Information pertinent to the use of these drug preparations in infants is well sum marized in the previous American Academy of Pediatrics statement. 100 Recent surveys have documented that, in accord with the recommendations of that statement, 94% of UK and 83% of US clinicians use an opioid (mor phine or methadone) as the drug of first choice. The majority of practi tioners use phenobarbital as a second drug if the opiate does not adequately control withdrawal signs. 102, 113 Daily doses of morphine ranged from 0.24 mg/kg per day to 1.3 mg/kg per day. 113 Paregoric is no longer used, because it contains variable concentrations of other opioids, as well as toxic ingre dients such as camphor, anise oil, al cohol, and benzoic acid. 100 The use of diazepam has also fallen into disfavor because of a documented lack of effi cacy compared with other agents and because of its adverse effects on infant [114] [115] [116] suck and swallow reflexes.
Meta-analyses of published trials re garding the pharmacologic treatment of neonatal withdrawal are available. 117, 118 In 2 Cochrane meta-analyses, either an opioid 117 or a sedative 118 Seven studies of opioid treatment that enrolled a total of 585 infants were identified between 1983 and 2004. Methodologic flaws were common and included quasirandom patient alloca tion; substantial and often unexplained differences in allocation of patients to treatment groups; imbalances in group characteristics after randomi zation; failure to mask study treat ments; and failure to mask outcome measurements. In the single study that assessed oral morphine treatment versus supportive therapy only, 3 con secutive Finnegan scores ≥8 promp ted institution of the intervention. 119 No significant effect of morphine was found on the rate of treatment failure. Oral morphine significantly increased the duration of treatment and the length of hospital stay, but it did re duce the number of days required to regain birth weight and duration of supportive care. Four studies com pared treatment failures of opioids (paregoric, oral morphine, or metha done) with phenobarbitone. 8, [119] [120] [121] Neither the meta-analysis nor any in dividual study identified a significant difference in treatment failure. One study reported a lower incidence of PEDIATRICS Volume 129, Number 2, February 2012 seizures in the opioid (paregoric) treatment group. 122 No consistent trends in secondary outcomes were observed, although 1 study reported a shorter duration of therapy in the phenobarbitone compared with the paregoric treatment group, 123 and another made the opposite observa tion when the opioid used was oral morphine. 121 Three studies individually and in combination reported signifi cantly lower rates of treatment failure in infants assigned to opioid (pare goric or methadone) compared with diazepam therapy 8, 114, 120 but did not define differences in secondary out comes. No studies reported mortality or neurodevelopmental outcomes.
A second Cochrane review analyzed 6 trials involving 305 infants published between 1969 and 2002 in which sed ative treatment of NAS was compared with a nonopioid therapy. Methodologic concerns were similar to the opioid treatment trials. In the sole study of phenobarbitone versus supportive care, no difference in treatment failure was found, but treatment significantly in creased the duration of therapy and hospital stay. 119 A small study that allocated infants already treated with diluted tincture of opium (DTO) to phe nobarbitone as a second drug versus no additional treatment identified no infants in either group with treatment failure but observed significant reduc tions in the duration of hospitalization (38 vs 79 days) and the maximal daily dose of opioid in the phenobarbitone treated infants. 124 Infants were dis charged from the hospital once they were no longer taking opioids. How ever, the mean duration of phenobar bitone treatment was 3.5 months. Of 3 studies that compared phenobarbi tone and diazepam treatment, 1 found a significantly lower rate of treat ment failure in the phenobarbitone group. 8, 114, 120 One study of phenobar bitone versus chlorpromazine 125 found no differences in primary or second ary outcomes.
Since 2004, a number of small studies of varying methodologic quality have compared pharmacologic treatments. In a prospective randomized double al 126 masked study, Langenfeld et could not identify differences in du ration of treatment, duration of hos pitalization, or in weight gain (g/day) in infants treated with either DTO or oral morphine drops. A retrospective study found no difference in length of hospitalization in infants with NAS who were treated with methadone or oral morphine solution, but did cor relate higher maternal methadone doses with longer lengths of stay. 127 Ebner et al 128 examined the incidence of NAS in infants born to mothers maintained with methadone, morphine, or buprenorphine and compared phe nobarbital and oral morphine treat ments in affected infants. Sixty-eight percent of infants born to mothers maintained on methadone required pharmacologic treatment at a mean age of 58 hours, compared with 82% of infants at a mean age of 33 hours in the morphine group and 21% of infants at a mean age of 34 hours in the buprenorphine group. The dura tion of treatment was significantly shorter for infants who received mor phine compared with infants who were treated with phenobarbital. A random ized comparison trial of sublingual buprenorphine versus neonatal opium solution for the treatment of NAS showed a nonsignificant reduction in length of treatment and duration of hospitalization in the buprenorphine group. 129 Buprenorphine therapy was well tolerated.
Clonidine is an α 2 -adrenergic receptor agonist that has been used in combi nation with an opioid or other drug in older children and adults to reduce withdrawal symptoms. 130, 131 Via a neg ative feedback mechanism, clonidine e549 reduces CNS sympathetic outflow and palliates symptoms of autonomic overactivity such as tachycardia, hyper tension, diaphoresis, restlessness, and diarrhea. Cessation of clonidine treat ment can result in a rebound of auto nomic activity. Reported experience with clonidine as a primary or ad junctive treatment of NAS is limited but promising. In a small case series, 6 of 7 infants with NAS showed signif icant resolution of signs when treated with oral clonidine. 132 In a randomized double-masked controlled trial, Agthe al 133 et compared the efficacy and safety of treating NAS with DTO plus oral clonidine (1 µg/kg every 3 hours) versus DTO plus placebo in 80 infants with prenatal exposure to methadone and/or heroin. The combination ther apy significantly reduced the median length of treatment of all infants and for infants exposed to methadone, but more infants in the DTO/clonidine group required resumption of DTO after initial discontinuation. The mean total dose of morphine over the treat ment course was ∼60% lower in the combination therapy group. No clini cally significant differences in feeding, weight gain or loss, heart rate, or blood pressure were observed. In another case series, oral clonidine was ad ministered either as a primary or adjunctive therapy for the prevention or treatment of narcotic withdrawal in infants on intravenous fentanyl or infants with antenatal exposure to opiates. 134 In all cases, treatment was successful and clonidine was discon tinued without sequelae after a mean duration of 7 days. In a retrospective case series, infants who had evidence of NAS attributable to antenatal meth adone exposure had lower severity scores and required fewer days of drug therapy and hospitalization if they had been treated with a combination of clonidine and chloral hydrate rather than a combination of morphine and phenobarbital. 135 A recently published case series from France that used a historical cohort for a comparison has suggested that the treatment of NAS with the pheno thiazine, chlorpromazine, as a single drug may be more effective than treat ment with morphine. 136 Infants treated with oral morphine had significantly longer median durations of treatment and hospitalization in comparison with infants treated with chlorpromazine. No adverse affects were reported. OUTCOME Assessment of potential long-term morbidity specifically attributable to neonatal drug withdrawal and its treatment is difficult to evaluate. Few studies have followed drug-exposed children beyond the first few years of life. Confounding variables, such as environment and dysfunctional care givers, complicates the interpretation of outcomes. In a small study, devel opmental scores on the mental index on the Bayley Scales of Infant Devel opment were not affected by the se verity of withdrawal or the treatment chosen. 114 Mean scores on the Bayley Scales of Infant Development were similar for all infants treated for withdrawal, including those receiving phenobarbital, paregoric, or a combina tion therapy. Scores of infants whose withdrawal was too mild to qualify for pharmacologic intervention were also similar.
Fourteen drug-exposed infants with withdrawal-associated seizures were reported by Doberczak et al. 25 The abstinence scores for 5 of these infants were <7 (the cutoff for treat ment); hence, they received no phar macologic therapy before the onset of seizures. Thirteen of the 14 infants were offspring of mothers enrolled in a methadone treatment program; how ever, the success of maternal treat ment was not described. Of the 14 infants with seizures, 12 were available for evaluation at 1 year of age; results of neurologic examinations were nor mal in 9 of the 12 infants evaluated. EEG results were abnormal in 9 neo nates; however, subsequent EEGs for 7 of 8 of these infants normalized during follow-up. Mean scores on the Bayley Scales of Infant Development were also normal by 1 year of age, similar to matched controls that were drug exposed, but in whom withdrawalassociated seizures did not develop. 24 Withdrawal-associated seizures seem to be primarily myoclonic, to respond to opiates, and to carry no increased risk of poor outcome. Withdrawalassociated seizures in neonates are different from those associated with other causes. Based on the depression of norepinephrine and dopamine ob served with methadone exposure in an imal models, withdrawal seizures are speculated to be attributable to low ered levels of neurotransmitters. 137, 138 The normalization of the EEG and nor mal neurologic development are be lieved to reflect recovery of normal neurotransmitter concentrations dur al 139 ing early infancy. Bandstra et have comprehensively reviewed out comes of infants and toddlers who were exposed prenatally to opioids and cocaine.
MANAGEMENT OF ACQUIRED OPIOID AND BENZODIAZEPINE DEPENDENCY
One of the cornerstones in caring for critically ill children is to provide ad equate and safe analgesia, sedation, amnesia, and anxiolysis by using both pharmacologic and nonpharmacologic measures. Pharmacologic treatment typically includes medications in the opioid and benzodiazepine drug clas ses. However, if these drugs cannot safely be discontinued within a few days, physical dependence on 1 or both of these classes of medication can develop and manifest with signs FROM THE AMERICAN ACADEMY OF PEDIATRICS and symptoms of withdrawal on acute dosage reduction or cessation of therapy. Infants who undergo complex surgery, who require prolonged med ical intensive care for conditions such as respiratory failure or persistent pulmonary hypertension, or who are supported with extracorporeal mem brane oxygenation (ECMO) therapy are among those at greatest risk of ac quired drug dependency.
Extended treatment with opioids via continuous intravenous infusion re sults in drug tolerance. Even shortterm opioid exposure alters the number and affinity of receptors in key neuronal centers so that an escala tion of the opioid infusion rate (which produces an increase in opioid plasma concentrations) becomes necessary to achieve the same physiologic effect. 140 By itself, the development of tolerance does not predict physical dependency or withdrawal. 141 Cumulative expo sure to fentanyl, quantified by the to tal dose in milligrams per kilogram or the number of consecutive days of treatment, correlated with the likeli hood of withdrawal. 140, 142, 143 By using a multiple logistic regression analysis, Arnold et al 140 found that the duration of ECMO therapy was an even more powerful predictor of withdrawal than was cumulative fentanyl exposure. Katz et al 142 reported that among 23 mechanically ventilated children aged 1 week to 22 months (mean, 6 months) who were treated for >24 hours with a continuous fentanyl infusion, 13 of 23 children (57%) developed withdrawal as defined by a Finnegan score ≥8. In this prospective study, a cumulative fen tanyl exposure in excess of 2.5 mg/kg or 9 days of therapy was 100% pre dictive of withdrawal. More recently, in a prospective study of 19 neonates treated with fentanyl for a minimum of 24 hours, Dominquez et al 143 docu mented that a cumulative fentanyl dose ≥415 µg/kg predicted withdrawal with PEDIATRICS Volume 129, Number 2, February 2012 70% sensitivity and 78% specificity and that an infusion duration ≥8 days was 90% sensitive and 67% specific for withdrawal. In adults, concomitant treatment with neuromuscular para lytic agents or propofol for >24 hours also increased the likelihood of with drawal. 144 Signs and symptoms of with drawal from fentanyl commence within 24 hours of cessation of therapy.
The refinement of pain management in children over the past 2 decades has witnessed an expansion of the use of opioids in the intensive care setting. As a result, more children have been treated for actual or potential with drawal symptoms as a comorbidity of hospitalization. Fentanyl, a pure µ-opioid receptor antagonist, has become the opioid of choice because of its rapid onset of action, short duration of ef fect (half-life of 0.5-1 hour), excellent potency, and minimal acute adverse effects. However, fentanyl has not been demonstrated to be safer or more ef fective than morphine for the provision of long-term analgesia. Indeed, 1 study has reported that patients who were treated prospectively with a continu ous morphine infusion during ECMO experienced a significantly lower need for supplemental analgesia, a lower rate of dependency, and a shorter hos pital stay compared with a previous group of patients treated with fentanyl during ECMO. 145 Practitioners have employed a variety of strategies to treat or, in high-risk patients, to prevent signs and symp toms of opioid withdrawal in infants and children. Carr and Todres 146 reported success with a gradual taper of the opioid infusion rate. Children who had received continuous opioid infusions for more than a week re quired 2 to 3 weeks for complete weaning. One disadvantage of this approach was that intravenous access had to be maintained for the entire course of treatment. Tobias et al 147 were among the first investigators to describe treatment of opioid with drawal by conversion to enteral methadone. Methadone was chosen as the opioid of choice because of its excellent oral bioavailability (70%-100%) and long half-life (19-41 hours), which allowed for long inter vals between doses. 148 In this initial report, 3 symptomatic patients who had been exposed to continuous or bolus opioids for up to 7 weeks were transitioned to a methadone regimen of 0.1 mg/kg, orally, every 12 hours. Dose reduction by 10% to 20% of the initial dose per week resulted in suc cessful weaning in 4 to 6 weeks. al 149 In 2000, Robertson and et re ported the outcomes of 10 children 6 months to 18 years of age who had received >7 days of opioids (range, 7-53 days). An amount of methadone, equipotent to the existing daily fen tanyl or morphine dose, was deter mined. This amount was reduced by a factor of 6 because of the longer half-life of methadone to calculate the initial total daily methadone dose. Protocols specified 2 different wean ing schedules, depending on whether the patient had been treated with opioids (fentanyl or morphine) for ei ther 7 to 14 days or for >14 days. Treatment intervals were gradually lengthened from every 6 hours to ev ery 24 hours when methadone was discontinued. Outcomes of these pa tients were compared with recent control patients who had also been treated with enteral methadone but not under a standard protocol. Among the protocol patients, there were no treatment failures. Weaning was ac complished in a median of 9 days (range, 5-10 days), which was signif icantly less than the median of 20 days (range, 9-31 days) observed in the nonprotocol children. Concurrent use of benzodiazepines occurred in 6 of the protocol children, compared with 3 of the nonprotocol group, so that the decreased taper time on protocol was unlikely to have been confounded by other drug therapy. Weaning and discontinuation from benzodiazepines were successful dur ing the methadone taper in all pro tocol patients.
Meyer et al 150 described a protocol for rescue therapy in 29 patients 1 day to 20 years of age on admission who developed withdrawal during the course of nonstandardized tapers of prolonged continuous fentanyl in fusion. Withdrawal was defined as the observation of 3 consecutive Finnegan scores ≥8 obtained at 2-hour inter vals. The daily fentanyl dose for the period 24 to 48 hours before with drawal symptoms was used to calcu late an equipotent dose of morphine sulfate. Morphine was administered as a bolus dose every 4 hours and titrated to effect (Finnegan score consistently <8) over 12 to 24 hours. An equipotent amount of methadone was then determined by using the effective morphine dose. Three load ing doses of methadone at 12-hour intervals were administered. After ward, doses were given every 24 hours and weaned by 10% per day. Ten patients were receiving concomi tant treatment with a benzodiazepine or chloral hydrate, but these medi cations were not weaned during the methadone taper. Twenty-five of 29 patients successfully completed this taper over 10 days. Three patients required 21 days, and 1 patient died of sepsis. Sixteen of the patients were discharged from the hospital and completed methadone tapers on an outpatient basis. Nine of the patients had been started on clonidine during the phase of nonstandardized opioid weaning in unsuccessful attempts to prevent withdrawal. A subsequent ran domized double-blind follow-up study by the same group of investigators 151 found that in a group of 37 fentanyl treated patients, a 5-day methadone taper was as successful as the longer 10-day course (13 of 16 vs 17 of 21 [not significant]) in discontinuing opi oid infusions without causing with drawal. In contrast to their previous study, a standardized taper of lor azepam was allowed in 17 of the 37 patients while on the methadone protocol. Only 1 of these 17 patients who underwent dual tapers required rescue treatment with an increased dose of opioids.
Several factors potentially complicate the adoption of the protocols reported by Robertson, Meyer, and Berens (see Table 4 ) into routine neonatal clinical practices. Most obvious is that these studies were conducted in a PICU setting; few neonates were included, and their outcomes were not sepa rately analyzed. Other investigators have emphasized that the Finnegan instrument common to all 3 studies has been validated only in term in fants undergoing withdrawal secondary 152, 153 to in utero opioid exposure. Therefore, the use of this tool may have underestimated withdrawal symp tomatology in an older pediatric pop ulation. A third concern is that opioids and benzodiazepines are often used concurrently in the same patient, yet symptoms of opioid and benzodiaze pine withdrawal overlap to a great ex tent. Hence, current instruments will not reliably differentiate whether with drawal symptoms stem from relative opioid or benzodiazepine abstinence. 153 Other scales have been proposed for children and are in various stages of evaluation, including the Opioid and Benzodiazepine Withdrawal Scale, 151 the Sedation Withdrawal Score, 154 and the Sophia Benzodiazepine and Opioid Withdrawal Checklist. 155 At this time, no optimal pharmacologic regimen for the prevention or treat ment of acquired opioid and/or benzodiazepine dependency can be recommended, because the necessary comparative studies of safety and ef ficacy are not available. 156 Hence, it is even more incumbent on the practi tioner to prescribe pharmacologic interventions with the goal of achiev ing the desired therapeutic effect by using the fewest drugs at the lowest doses and for the shortest durations possible.
Nonetheless, because many critically ill infants and children do receive treat ment with prolonged courses of opioids and benzodiazepines, the following practices are reasonable based on the available evidence: calculated methadone equivalent to achieve a successful conversion. Also, the rate of weaning should be adjusted on the basis of careful con tinuing clinical assessment. Eighty percent of children can be success fully weaned from methadone com pletely within 5 to 10 days.
4. Signs and symptoms of withdrawal from benzodiazepine therapy can be delayed. Intravenous benzodia zepines can be converted to oral lorazepam ( Table 4 ). The required time for weaning can be expected to be proportional to the dura tion of intravenous benzodiazepine treatment. 6) The optimal threshold score for the institution of pharmacologic therapy by using any of the pub lished abstinence assessment in struments is unknown. 11) Physicians need to be aware that the severity of withdrawal signs, including seizures, has not been proven to be associated with dif ferences in long-term outcome af ter intrauterine drug exposure. Furthermore, treatment of drug withdrawal may not alter the long-term outcome.
12) Given the natural history of with drawal, it is reasonable for neo nates with known antenatal exposure to opioids and benzo diazepines to be observed in the hospital for 4 to 7 days. After discharge, outpatient follow-up should occur early and include reinforcement of the education of the caregiver about the risk of late withdrawal signs.
13) Neonates cared for in ICUs who
have developed tolerance to opioids and benzodiazepines as a result of an extended duration of treat ment can be converted to an equivalent regimen of oral meth adone and lorazepam. Doses may be increased as necessary to achieve patient comfort. These med ications can then be reduced by 10% to 20% of the initial dose every 1 to 2 days on the basis of clinical response and serial assessments by using a standardized neonatal abstinence instrument.
14) Significant gaps in knowledge concerning the optimal treatment strategy (including the criteria for instituting pharmacologic ther apy, the drug of first choice, and the strategy for weaning) of infants with neonatal withdrawal should be addressed in well-designed randomized controlled studies that are adequately powered to assess short-term outcomes and to provide for long-term follow-up.
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